New fast-acting insulin added to PBS to replace delisted drugs
The Fiasp Penfill listing follows negotiations between the Federal Government and Novo Nordisk.
Patients with types 1 diabetes will continue to have subsidised access to fast-acting insulin, with the approval of a new product to replace Fiasp and Fiasp FlexTouch.
On Monday, federal Minister for Health and Aged Care Mark Butler announced that Fiasp Penfill would be added to the PBS from October following negotiations with Novo Nordisk.
“The Albanese Government has worked hard to secure an ongoing solution to the commercial decision to delist the original products,” Mr Butler said.
The new fast-acting insulin aspart product will be listed on the PBS under the same conditions and criteria as Fiasp and Fiasp FlexTouch.
